Adaptive Biotechnologies Corp (ADPT) stock
ADPTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 12/30322% above fair value
$29.04−0.44 (-1.49%)
Close on Nov 13, 2026Market cap $4.63BP/E –Yield –
Adaptive Biotechnologies ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Adaptive Biotechnologies's ebitda for the twelve months ending Mar 31, 2026 was -$31.64M. For fiscal 2025 it was -$41.12M.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$41.12M | – |
| FY2024 | Dec 31, 2024 | -$145.11M | – |
| FY2023 | Dec 31, 2023 | -$207.44M | – |
| FY2022 | Dec 31, 2022 | -$179.27M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2026 | Mar 31, 2026 | -$15.82M | – |
| Q4 FY2025 | Dec 31, 2025 | -$9.12M | – |
| Q3 FY2025 | Sep 30, 2025 | $14.26M | – |
| Q2 FY2025 | Jun 30, 2025 | -$20.97M | – |
| Q1 FY2025 | Mar 31, 2025 | -$25.32M | – |
| Q4 FY2024 | Dec 31, 2024 | -$29.91M | – |
| Q3 FY2024 | Sep 30, 2024 | -$28.48M | – |
| Q2 FY2024 | Jun 30, 2024 | -$42.75M | – |
| Q1 FY2024 | Mar 31, 2024 | -$43.55M | – |
| Q4 FY2023 | Dec 31, 2023 | -$68.31M | – |
| Q3 FY2023 | Sep 30, 2023 | -$45.19M | – |
| Q2 FY2023 | Jun 30, 2023 | -$42.17M | – |
| Q1 FY2023 | Mar 31, 2023 | -$51.77M | – |
See a number that looks wrong?